Land of opportunity Since AstraZeneca has quite a presence in the U.S. healthcare market and does much of its business in the country, it makes abundant sense to shift the main stock market ...

Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. CEO Pascal Soriot is ...

(Reuters) -AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the United States, the Times reported on Tuesday, citing ...

Pharmalittle: We’re reading about Spain probing Novo weight loss ads, AstraZeneca stock listing, and more Trump administration terminates millions in funding for publishing giant Springer Nature ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the United States, the Times reported on Tuesday, citing multiple sources.

AstraZeneca 's CEO, Pascal Soriot, has reportedly held private discussions about moving the pharmaceutical firm's stock market listing from London to the US.